NOX:
Market Cap:
Price Delay ~20min
Entitlement Offer Prospectus
May/June 2020

Management Team

Gisela Mautner

Dr Gisela Mautner

Chief Medical Officer

MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia)

Dr Mautner brings a wealth of experience to her role as Chief Medical Officer, having held medical leadership roles in the pharma and biotech industry in the USA, Europe and Australia.  As a medical doctor, she is dedicated to making the lives of patients better, and as an industry advocate, she is excited by new developments in treatments that provide new hope to many people. 

In her early career she was a research scientist at the National Institutes of Health (NIH) in Bethesda, MD, USA and at the Kyoto Prefectural University in Kyoto, Japan. She transitioned to the pharma industry to focus on taking new drugs out of the lab and making them widely available to patients.  She has had many successes launching new products for Merck (MSD), Bayer and Amgen. She is proud of her leadership role in one of the most successful drug launches in Australia.

For the last decade her passion has been new therapies in oncology. Her interests encompass small molecules, biologics, gene-modified viruses and radiopharmaceuticals for many different cancer types and from early to late stage disease. She fuels her passion with the knowledge that her efforts improve the life of patients on a daily basis.  Balancing patient care and commercial interests has been part of her responsibilities as the medical lead throughout most of her career as well as directing the medical strategies and operations, budget management, compliance and staff performance in Medical Affairs Departments of multinational companies.

Dr Mautner has built and nurtured a broad network of medical doctors, especially oncologists in Australia and in the USA.  In addition, she is extensively connected to pharmaceutical professionals in Australia as well as in the USA through her work as the President of the Australian Association for medical and scientific Professionals in the Pharmaceutical industry (APPA) which has recently entered into a partnership with the US based Medical Affairs Professional Society (MAPS).

Having lived and worked in several countries, Dr Mautner is attuned to not only the commercial but also to cultural implications of launching new drugs in foreign territories. As Noxopharm negotiates its global journey, Dr Mautner’s language skills will be invaluable. She is fluent in English and German and has intermediary skills in Japanese and French.

Jeanette Bell

Jeanette Bell

Chief Operating Officer

BMedSc, MScM

Jeanette joined Noxopharm in 2019, with over 30 years’ experience in the private, public and corporate healthcare sectors. This included 15 years with Lilly Pharmaceuticals in positions spanning Clinical Research, Clinical Portfolio Management, Medical Affairs, Medical and Commercial Operations, Drug Development, Sales and Marketing settings and Launch Excellence Management. Through these diverse tenures, Jeanette developed a deep understanding on the mechanisms (and challenges) associated with progressing assets through the drug development pipeline to market.

The opportunity in the pharmaceutical industry to hold leadership positions across Australia, New Zealand, Europe, Asia Pacific (mid-size countries) China, and Japan - has afforded Jeanette deep insights into the intricate strategic frameworks required to deliver a strategic vision across multiple regions and stakeholder groups.

As Chief Operating Officer at Noxopharm, Jeanette is tasked to implement an operations framework to deliver the Clinical Development Plan. This includes creating processes for strategic planning and prioritization of projects, resourcing of projects, vendor management, and the implementation of systems and processes for Quality Assurance and Data Risk Management. Jeanette is also involved in Business Development activities for Noxopharm.

Jeanette holds Bachelor of Medical Science (BMedSc) and Master of Science Management (MScM) degrees and operations related qualifications in Portfolio Management (PMO) and Six Sigma Methodologies.

Shawn Van Boheemen

Shawn Van Boheemen

Chief Financial Officer

BBus MCom, FCPA JP

Shawn has 30 years' experience in commercial finance leadership positions across a range of manufacturing, service based and financial services industries. He has worked in senior financial positions for a number of both Australian and multinational organisations, including Covance, Unomedical, M.D. Sass and New York Life Insurance. Shawn has a Bachelor of Business Degree in Accounting and Commercial Law, a Master of Commerce Degree with a major in Accounting, is a Fellow of the Australian Society of Certified Practising Accountants and Justice of the Peace in NSW.  Shawn has experience in the contract research and medical devices industries, along with printing/packaging, software and investment management.  His responsibilities have included a number of company secretarial positions, head of compliance, head of information technology, administration and human resources, warehousing and inventory management.

Shawn has experience with both Australian ASX and ASIC reporting, SEC reporting in the U.S., compliance and regulatory affairs matters, intellectual property protection and regulatory and financial reporting both in Australia and the U.S. He spent three years in a global software company as an analyst and Asia Pacific business development manager to further broaden his commercial skillset. He joined Noxopharm Limited in March 2019 and brings a wide range of commercial and financial skills to the organisation.

John Wilkinson

Dr John Wilkinson

Chief Scientific Officer

PhD, BSc Hons

John brings over 30 years of experience from both pharmaceutical and research settings in Australia and the United Kingdom, with a focus on the development of small molecules to target viruses and cancer.  John graduated from the University of Portsmouth (BSc Hons) in 1988 and has a PhD in HIV-1 Immunovirology from the University of NSW.  His research interests include Drug Development, Virology, Oncology and Immunology, translating novel laboratory findings into human clinical trials that have previously resulted in numerous peer-reviewed publications.  Prior to joining Noxopharm, John was the Chief Scientific Officer at Biotron Limited, where he was responsible for the oversight of Biotron's antiviral programs and instrumental in the HIV-1 clinical programs.  At Noxopharm, John will manage the scientific, research and technological operations of the company, help set company research and scientific priorities that align with the company's mission and vision.

Olivier Laczka

Director of Drug Discovery and Research

PhD  

Dr Laczka obtained a PhD in Biotechnology from the Autonomous University of Barcelona, Spain, in 2009, after completing a master’s degree in applied biotechnology and microbiology and a bachelor’s degree in biological sciences in France. For the first part of his career, Olivier conducted research as an academic, in Spain and Australia, where he was able to successfully develop diagnostic tools toward a wide range of applications, going from medical and food diagnostics to both terrestrial and marine monitoring devices, generating over 25 peer-reviewed research articles and patents. In 2012, he was awarded the prestigious University of Technology Sydney (UTS) Vice Chancellor’s Postdoctoral Research Fellowship, which enabled him to carry out extensive independent research on the development of novel methods toward the detection of human pathogens.

Dr Laczka’s expertise covers an extensive range of technical skills in microscopy, chemical, electrochemical and optical methods, microbiology, biochemistry, immunology, and molecular biology. In 2015, he joined the Biopharmaceutical industry as a senior research scientist, where he successfully managed and completed therapeutic drug development projects within GLP and cGMP environments, following the current regulatory requirements for early stages of drug development. Throughout his career, Olivier has developed an extensive experience in people and project management, as well as interacting with academic, government, and private entities or individuals, at the international level. His scientific writing experience has also allowed him to attract significant amounts of research funding over the years, through collaborations and partnerships with private entities and government organizations.